Interestingly, MT1-dependent mechanisms of melatonin action were defective in AR-null, but not AR-intact, prostate cancer cells, which may further imply a functional interplay between melatonin-MT1 axis and AR signaling. This evidence concerns the gene MTNR1A and prostate carcinoma.